Jump to content

Fosigotifator

From Wikipedia, the free encyclopedia
Fosigotifator
Clinical data
Other namesABBV-CLS-7262; Fosigotifator sodium tromethamine
Legal status
Legal status
  • Investigational
Identifiers
  • [(2S)-1,4-Bis[[2-(4-chloro-3-fluorophenoxy)acetyl]amino]-2-bicyclo[2.2.2]octanyl]oxymethyl dihydrogen phosphate
CAS Number
PubChem CID
UNII
Chemical and physical data
FormulaC25H27Cl2F2N2O9P
Molar mass639.37 g·mol−1

Fosigotifator is an experimental small-molecule developed by AbbVie, which is running clinical trials to determine if the drug can treat amyotrophic lateral sclerosis (ALS).[1][2][3] A formulation of fosigotifator, as its monosodium phosphate salt mixed with tromethamine, is known as ABBV-CLS-7262. Fosigotifator has been patented by AbbVie and Calico Life Sciences as a prodrug for modulation of the integrated stress response pathway.[4]

References

[edit]
  1. ^ Arnold, F. J.; Nguyen, A. D.; Bedlack, R. S.; Bennett, C. L.; La Spada, A. R. (1 August 2023). "Intercellular transmission of pathogenic proteins in ALS: Exploring the pathogenic wave". Neurobiology of Disease. 184: 106218. doi:10.1016/j.nbd.2023.106218. ISSN 0969-9961. PMID 37394036. S2CID 259300396.
  2. ^ Martinez-Gonzalez, Loreto; Martinez, Ana (1 February 2023). "Emerging clinical investigational drugs for the treatment of amyotrophic lateral sclerosis". Expert Opinion on Investigational Drugs. 32 (2): 141–160. doi:10.1080/13543784.2023.2178416. hdl:10261/308825. ISSN 1354-3784. PMID 36762798. S2CID 256738008.
  3. ^ Cho, William; Jeong, Anna; Malik, Paul; Boiser, Joey; Huang, Xiu; Rosebraugh, Matthew (25 April 2023). "A Phase 1 First-in-human Study to Investigate the Safety, Tolerability and Food Effect of ABBV-CLS-7262 (P6-4.002)". Neurology. 100 (17 Supplement 2): 4188. doi:10.1212/WNL.0000000000203810. ISSN 0028-3878. S2CID 258416815.
  4. ^ WO 2020077217, "Prodrug Modulators of the Integrated Stress Pathway", published 2020-04-16